[go: up one dir, main page]

DE60006584D1 - Verwendung von beta-rezeptorenblocker zur herstellung eines medikaments zur behandlung von krankheiten der äusseren retina - Google Patents

Verwendung von beta-rezeptorenblocker zur herstellung eines medikaments zur behandlung von krankheiten der äusseren retina

Info

Publication number
DE60006584D1
DE60006584D1 DE60006584T DE60006584T DE60006584D1 DE 60006584 D1 DE60006584 D1 DE 60006584D1 DE 60006584 T DE60006584 T DE 60006584T DE 60006584 T DE60006584 T DE 60006584T DE 60006584 D1 DE60006584 D1 DE 60006584D1
Authority
DE
Germany
Prior art keywords
producing
treating diseases
medicinal product
receptor blockers
beta receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60006584T
Other languages
English (en)
Other versions
DE60006584T2 (de
Inventor
J Collier
A Kapin
Desantis, Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Application granted granted Critical
Publication of DE60006584D1 publication Critical patent/DE60006584D1/de
Publication of DE60006584T2 publication Critical patent/DE60006584T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE60006584T 1999-11-30 2000-11-29 Verwendung von beta-rezeptorenblocker zur herstellung eines medikaments zur behandlung von krankheiten der äusseren retina Expired - Lifetime DE60006584T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16799399P 1999-11-30 1999-11-30
US167993P 1999-11-30
PCT/US2000/032575 WO2001043737A1 (en) 1999-11-30 2000-11-29 Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina

Publications (2)

Publication Number Publication Date
DE60006584D1 true DE60006584D1 (de) 2003-12-18
DE60006584T2 DE60006584T2 (de) 2004-09-30

Family

ID=22609644

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60006584T Expired - Lifetime DE60006584T2 (de) 1999-11-30 2000-11-29 Verwendung von beta-rezeptorenblocker zur herstellung eines medikaments zur behandlung von krankheiten der äusseren retina

Country Status (18)

Country Link
US (4) US7081482B2 (de)
EP (1) EP1244438B1 (de)
JP (2) JP4758581B2 (de)
CN (1) CN1245966C (de)
AT (1) ATE253905T1 (de)
AU (1) AU782524B2 (de)
BR (1) BR0015938A (de)
CA (1) CA2388728C (de)
DE (1) DE60006584T2 (de)
DK (1) DK1244438T3 (de)
ES (1) ES2210023T3 (de)
HK (1) HK1047695B (de)
MX (1) MXPA02005378A (de)
PL (1) PL214875B1 (de)
PT (1) PT1244438E (de)
TR (1) TR200302008T4 (de)
WO (1) WO2001043737A1 (de)
ZA (1) ZA200203133B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60006584T2 (de) * 1999-11-30 2004-09-30 Alcon, Inc. Verwendung von beta-rezeptorenblocker zur herstellung eines medikaments zur behandlung von krankheiten der äusseren retina
CN100413503C (zh) * 2005-01-07 2008-08-27 冷文 一种复方眼药组合物
US20080153819A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
WO2009110009A2 (en) * 2008-03-07 2009-09-11 Sun Pharma Advanced Research Company Ltd., Opthalmic composition
US10267796B2 (en) * 2010-10-25 2019-04-23 The Procter & Gamble Company Screening methods of modulating adrenergic receptor gene expressions implicated in melanogenesis
JP7171611B2 (ja) * 2017-04-21 2022-11-15 スティーブン・ホフマン 網膜症を治療するための組成物及び方法
WO2019213358A1 (en) * 2018-05-03 2019-11-07 Alimera Sciences, Inc. Methods of treating retinal diseases
JP7392219B2 (ja) * 2020-01-20 2023-12-06 株式会社萌芽プランツ フラボノイド組成物
JP2023533911A (ja) * 2020-07-10 2023-08-07 チャン グァン メモリアル ホスピタル，リンコウ 上皮成長因子受容体阻害剤によって誘発される上皮細胞損傷を軽減し及び癌細胞を阻害する組成物の製造のための、β－１アドレナリン受容体アンタゴニストの使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2330383A1 (fr) 1975-11-06 1977-06-03 Synthelabo Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment
US4443432A (en) 1981-10-05 1984-04-17 Alcon Laboratories, Inc. Ophthmalic irrigating solution
US5554367A (en) * 1984-10-31 1996-09-10 Alcon Laboratories, Inc. Compositions for treatment of glaucoma
US6066675A (en) 1996-09-13 2000-05-23 The Regents Of The University Of California Method for treatment of retinal diseases
BR9913955A (pt) * 1998-09-25 2001-06-12 Alcon Lab Inc Composição oftalmológica confortável e de liberação sustentada e método para terapia ocular
DE60006584T2 (de) * 1999-11-30 2004-09-30 Alcon, Inc. Verwendung von beta-rezeptorenblocker zur herstellung eines medikaments zur behandlung von krankheiten der äusseren retina

Also Published As

Publication number Publication date
TR200302008T4 (tr) 2004-01-21
ES2210023T3 (es) 2004-07-01
DE60006584T2 (de) 2004-09-30
MXPA02005378A (es) 2005-02-25
EP1244438B1 (de) 2003-11-12
AU782524B2 (en) 2005-08-04
CN1245966C (zh) 2006-03-22
CN1402634A (zh) 2003-03-12
BR0015938A (pt) 2002-08-27
US20080103211A1 (en) 2008-05-01
JP4758581B2 (ja) 2011-08-31
WO2001043737A1 (en) 2001-06-21
ATE253905T1 (de) 2003-11-15
PL356001A1 (en) 2004-05-31
JP2010215667A (ja) 2010-09-30
US20100249134A1 (en) 2010-09-30
AU2052701A (en) 2001-06-25
PT1244438E (pt) 2004-02-27
EP1244438A1 (de) 2002-10-02
CA2388728A1 (en) 2001-06-21
HK1047695A1 (en) 2003-03-07
PL214875B1 (pl) 2013-09-30
CA2388728C (en) 2009-05-19
US20060199868A1 (en) 2006-09-07
DK1244438T3 (da) 2004-02-23
HK1047695B (en) 2004-08-20
US7081482B2 (en) 2006-07-25
US8710102B2 (en) 2014-04-29
JP2003516963A (ja) 2003-05-20
US20020193373A1 (en) 2002-12-19
ZA200203133B (en) 2003-04-22

Similar Documents

Publication Publication Date Title
ATE284693T1 (de) Verwendung von dopamin-d 3-rezeptorantagonisten zur herstellung von arzneimittel für die behandlung von nierenfunktionsstörungen
ATE248599T1 (de) Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen
JO1605B1 (en) Derivatives 2- aminopyrimidone
ATE295170T1 (de) Verwendung von einem antagonist der zentralen kannabinoidrezeptoren zur herstellung von arzneimitteln
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
DE69713032D1 (de) Verwendung von SCF für Behandlung der Cornea
ATE293989T1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
DE69911380D1 (de) Verwendung von isatin- und oxindolderivaten zur herstellung von arzeneimittel für die behandlung von mykobakteriellen erkrankungen
DE69510928D1 (de) Heterocyclische verbindungen, ihre herstellung und verwendung
DE69022501D1 (de) Verwendung eines Amylinantagonisten zur Herstellung eines Artzneimittels zur Behandlung von Fettsucht und essentieller Hypertonie und damit zusammenhängenden Krankheiten.
DE60029929D1 (de) VERWENDUNG VON PYRIDAZINO i4,5-(b)ö-INDOLE-1-ACETAMIDE DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS ZUR BEHANDLUNG VON DURCH PERIPHERE BENZODIAZEPINREZEPTOREN-STÖRUNGEN VERURSACHTE KRANKHEITEN
DE60006584D1 (de) Verwendung von beta-rezeptorenblocker zur herstellung eines medikaments zur behandlung von krankheiten der äusseren retina
DE60129518D1 (de) Verwendung von einem Vasopressin-Antagonisten wie Conivaptan zur Herstellung eines Medikaments für die Behandlung der pulmonalen Hypertension
ATE520669T1 (de) 1,2-diarylbenzimidazole zur behandlung von erkrankungen die mit einer microglia-aktivierung assoziiert sind
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
DE60015508T2 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
DE59904180D1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
TR199700956T1 (xx) Indazolkarboksamidler.
DE69130679D1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
TR200200278T2 (tr) Kalsilitik bileşimler
DE69836858D1 (de) Verwendung von hyaluronidase zur herstellung eines augenpräparats zur glasskörperverflüssigung bei der behandlung von augenerkrankungen
ATE157354T1 (de) Verwendung von cucurbitine zur herstellung einer kosmetischen oder pharmazeutischen zusammensetzung zur dermatologischen, anti- allergischen anwendung
DE60128911D1 (de) Verwendung von l-threo-methylphenidat zur herstellung eines medikamentes zur behandlung von psychischen erkrankungen
DE69515666D1 (de) VERWENDUNG VON GnRH-ANTAGONISTEN ZUR HERSTELLUNG EINES MEDIKAMENTS ZUR BEHANDLUNG GONADEN-STEROID ABHÄNGIGER ERKRANKUNGEN
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition